Literature DB >> 19693098

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

B J Passer1, C-l Wu, S Wu, S D Rabkin, R L Martuza.   

Abstract

Oncolytic herpes simplex viruses type 1 (oHSVs) such as G47Delta and G207 are genetically engineered for selective replication competence in cancer cells. Several factors can influence the overall effectiveness of oHSV tropism, including HSV-1 receptor expression, extracellular matrix milieu and cellular permissiveness. We have taken advantage of human prostate organ cultures derived from radical prostatectomies to investigate oHSV tropism. In this study, we show that both G47Delta and G207 specifically replicate in epithelial cells of the prostatic glands but not in the surrounding stroma. In contrast, both the epithelial and stromal cell compartments were readily infected by wild-type HSV-1. Analysis of oHSV replication in prostate surgical specimens 3 days post infection showed that G47Delta generated approximately 30-fold more viral progeny than did G207. This correlated with the enhanced expression of G47Delta-derived glycoprotein gB protein levels as compared with G207. In benign prostate tissues, G207 and G47Delta titers were notably reduced, whereas strain F titers were maintained at similar levels compared with prostate cancer specimens. Overall, our results show that these oncolytic herpes vectors show both target specificity and replication competence in human prostate cancer specimens and point to the utility of using human prostate organ cultures in assessing oHSV tropism and cellular specificity.

Entities:  

Mesh:

Year:  2009        PMID: 19693098      PMCID: PMC2836587          DOI: 10.1038/gt.2009.94

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  28 in total

1.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.

Authors:  T J Jorgensen; S Katz; E K Wittmack; S Varghese; T Todo; S D Rabkin; R L Martuza
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

3.  p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.

Authors:  J K Parsons; W R Gage; W G Nelson; A M De Marzo
Journal:  Urology       Date:  2001-10       Impact factor: 2.649

4.  Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model.

Authors:  C G Miller; N W Fraser
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

5.  Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy.

Authors:  K A Delman; J J Bennett; J S Zager; B M Burt; P F McAuliffe; H Petrowsky; D A Kooby; W G Hawkins; B C Horsburgh; P Johnson; Y Fong
Journal:  Hum Gene Ther       Date:  2000-12-10       Impact factor: 5.695

6.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.

Authors:  P Sundaresan; W D Hunter; R L Martuza; S D Rabkin
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.

Authors:  S Varghese; J T Newsome; S D Rabkin; K McGeagh; D Mahoney; P Nielsen; T Todo; R L Martuza
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

Review 8.  The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells.

Authors:  G Campadelli-Fiume; F Cocchi; L Menotti; M Lopez
Journal:  Rev Med Virol       Date:  2000 Sep-Oct       Impact factor: 6.989

9.  Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia.

Authors:  J Choi; I Shendrik; M Peacocke; D Peehl; R Buttyan; E F Ikeguchi; A E Katz; M C Benson
Journal:  Urology       Date:  2000-07       Impact factor: 2.649

Review 10.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Authors:  Roberto Cattaneo; Tanner Miest; Elena V Shashkova; Michael A Barry
Journal:  Nat Rev Microbiol       Date:  2008-07       Impact factor: 60.633

View more
  9 in total

1.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Authors:  Brent J Passer; Tooba Cheema; Bingsen Zhou; Hiroaki Wakimoto; Cecile Zaupa; Mani Razmjoo; Jason Sarte; Shulin Wu; Chin-lee Wu; James W Noah; Qianjun Li; John K Buolamwini; Yun Yen; Samuel D Rabkin; Robert L Martuza
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

3.  Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.

Authors:  Tomoya Kato; Mikihito Nakamori; Shuichi Matsumura; Masaki Nakamura; Toshiyasu Ojima; Hiroshi Fukuhara; Yasushi Ino; Tomoki Todo; Hiroki Yamaue
Journal:  Oncol Lett       Date:  2021-04-23       Impact factor: 2.967

Review 4.  Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.

Authors:  Alicia Teijeira Crespo; Stephanie Burnell; Lorenzo Capitani; Rebecca Bayliss; Elise Moses; Georgina H Mason; James A Davies; Andrew J Godkin; Awen M Gallimore; Alan L Parker
Journal:  Immunology       Date:  2021-03-28       Impact factor: 7.215

5.  Stability and anti-tumor effect of oncolytic herpes simplex virus type 2.

Authors:  Yang Wang; Jing Jin; Zhen Wu; Sheng Hu; Han Hu; Zhifeng Ning; Yanfei Li; Yuting Dong; Jianwen Zou; Zeyong Mao; Xiaotai Shi; Huajun Zheng; Shuang Dong; Fuxing Liu; Zhizheng Fang; Jiliang Wu; Binlei Liu
Journal:  Oncotarget       Date:  2018-05-15

Review 6.  Oncolytic herpes simplex virus and immunotherapy.

Authors:  Wenqing Ma; Hongbin He; Hongmei Wang
Journal:  BMC Immunol       Date:  2018-12-18       Impact factor: 3.615

Review 7.  Three-dimensional tumor cell cultures employed in virotherapy research.

Authors:  Linus D Kloker; Can Yurttas; Ulrich M Lauer
Journal:  Oncolytic Virother       Date:  2018-09-05

8.  A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma.

Authors:  Tomoki Todo; Yasushi Ino; Hiroshi Ohtsu; Junji Shibahara; Minoru Tanaka
Journal:  Nat Commun       Date:  2022-07-21       Impact factor: 17.694

9.  Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Authors:  B J Passer; T Cheema; S Wu; C-L Wu; S D Rabkin; R L Martuza
Journal:  Cancer Gene Ther       Date:  2012-11-09       Impact factor: 5.987

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.